Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Blood Pressure on Myocardial Work in Patients With Hypertension

NCT05062811

Hypertension; Heart Disease, Hypertensive

UNKNOWN

The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis

NCT01703780

Hypertension, Resistant to Conventional Therapy

UNKNOWN

Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

NCT04107584

Hypertension

UNKNOWN

Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)

NCT03708601

Essential Hypertension

UNKNOWN

White Coat Hypertension and Antihypertensive Treatment Effect - SCOR in Hypertension

NCT00005316

Cardiovascular Diseases Heart Diseases Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. age ≥18 years; 2. male or female; 3. systolic blood pressure ≥140mmHg or (and) diastolic blood pressure \> 90mmHg; 4. history of hypertension\>1year, NYHA grade I-IV